KPTI


Karyopharm Falls 20% Despite Q4 Results Beat Estimates

This article was originally published on TipRanks.com Karyopharm Therapeutics, Inc.

Karyopharm (KPTI) Bulls Find More Reasons to Smile

The race for a COVID-19 treatment is in full throttle, as trials ramp up across the globe almost on a daily basis. On …

3 Healthcare Stocks With Important Catalysts in Q1

Blink, and you might just miss it. We are referring to the colossal gains that can be achieved by a select group of …

H.C. Wainwright Clips Price Target on Karyopharm Therapeutics Inc (KPTI), Still Sees Silver Lining as Shares Drop 16%

Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares are falling 16% after the biotech firm’s Phase 2 trial evaluating Selinexor in Older Patients with Relapsed Acute …

Karyopharm Therapeutics Inc (KPTI) and The Multiple Myeloma Research Foundation Announce Panel Discussion

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) together with the Multiple Myeloma Research Foundation (MMRF) announced that Karyopharm will host an investor and analyst dinner reception …

Company Update (NASDAQ:KPTI): Karyopharm Therapeutics Inc Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication

Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced that preclinical and Phase 1 clinical data describing XPO1 inhibition with selinexor (KPT-330), the Company’s lead, oral Selective Inhibitor …

Company Update (NASDAQ:KPTI): Karyopharm Therapeutics Inc Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor

Karyopharm Therapeutics Inc (NASDAQ:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from its Phase 2b STORM study evaluating the activity of selinexor …

Company Update (NASDAQ:KPTI): Karyopharm Therapeutics Inc Presents Preliminary STOMP Phase 1b Clinical Data at 2016 EHA Annual Meeting

Karyopharm Therapeutics Inc (NASDAQ:KPTI), a clinical-stage pharmaceutical company, today announced a poster presentation highlighting updated clinical data from the Company’s ongoing Phase 1b …

Wednesday’s Biotech Losers: ACADIA Pharmaceuticals Inc. (ACAD), Cempra Inc (CEMP), Karyopharm Therapeutics Inc (KPTI)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares closed down about 13% after the company announced a proposed public offering of its common stock yesterday.

Company Update (NASDAQ:KPTI): Karyopharm Therapeutics Inc to Present Clinical Data Update for Selinexor (KPT-330) in Hematologic Malignancies

Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced the presentation of clinical data for its lead drug candidate, selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts